Magnesiocard
Pancreatitis
University Medicine GreifswaldPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Pancreatitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOMIDATE Cheju Halla General Hospital | Phase 4 | BB |
Meperidine Cheju Halla General Hospital | Phase 4 | BB |
MIDAZOLAM Cheju Halla General Hospital | Phase 4 | BB |
MAGNESIUM METALLICUM University Medicine Greifswald | Phase 3 | BB |
Octreotide Pamoate Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 4 | BB |
View all 10 →
Same molecule, other indications
Magnesiocard is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →